According to Bloomberg, the sixteen research firms presently watching Arvinas, Inc. (NASDAQ: ARVN) have given the stock an average rating of “Moderate Buy,” indicating that they intend to purchase the company’s shares shortly. Eleven market analysts have provided a buy recommendation for the stock, while only three have urged that investors maintain their current holdings of the security. The average price objective analysts tracking the company for the past year have set for the company’s stock over the next year is $83.47. There have been several equity analysts that have provided their perspectives on the ARVN shares. In a research note made available to the public on Monday, August 8th, Oppenheimer lowered their price objective on Arvinas shares from $108.00 to $102.00 while maintaining their “outperform” rating on the business. In a research report released on Thursday, May 5th, Stifel Europe maintained a “buy” recommendation on the business, despite lowering their target price on Arvinas shares from $85.00 to $82.00. The report was about the company that was named Arvinas. In a research report made public on Friday, August 5th, Cantor Fitzgerald announced that they had reduced their price objective for Arvinas from $140.00 to $115.00. On the 21st of June, when a research note about Arvinas was made public, Jefferies Financial Group initiated coverage of Arvinas. They recommended keeping a “hold” position and setting the price objective at $42.00 for the stock. In a research report released on Friday, August 5th, Credit Suisse Group downgraded Arvinas from “outperform” to “98.00,” but this is not the least important change. On Tuesday, trading began for NASDAQ: ARVN for $41.96. The moving average for the company over the past 200 days is $54.53, while the moving average for the past 50 days is $48.92. The firm’s market capitalization is currently sitting at $2.23 billion, its price-to-earnings ratio is currently sitting at -9.41, and its beta value currently sits at 2.00. The price of Arvinas has ranged from $34.90 to $98.67 during the past 52 weeks. The most recent earnings report for Arvinas, denoted by the ticker symbol NASDAQ: ARVN, was published on August 4th. The earnings per share (EPS) for the quarter came in at a loss of $1.32, which was $0.28, worse than the average forecast of $1.00 per share.
Avinash’s return on equity was negative by 31.16%, and the company’s net margin was negative by 255.97%. The total revenue for the quarter came in at $31.30 million, which was significantly more than the average expectation of $23.71 million. During the same period the previous year, the company generated a loss of $1.03 per share. The increase in revenue for the quarter was 469.1% higher than during the same quarter the previous year. Arvinas’s earnings per share are expected to come in at -4.72 cents this year, according to projections made by sell-side analysts. On Friday, August 12, an insider named Ronald Peck sold 1,258 shares of the company’s stock. This is another piece of news regarding Arvinas. At an average price of $68.99 per share, the sale of the shares generated a profit of $86,789.42. Following the acquisition, the insider has gained direct ownership of 8,154 company shares, currently valued at $562,544.46.
An SEC filing that provides more information about the transaction is currently available online at the website of the SEC. There is a 2.78% ownership stake in the company held by company insiders—recent sales of ARVN assets by several prominent investors. During the last three months of 2018, Profund Advisors LLC increased its holdings in Arvinas by 7.0%. After purchasing an additional 282 shares during the most recent quarter, Profund Advisors LLC now owns 4,303 shares of the company’s stock, currently valued at $353,000. During the most recent quarter, Invesco Ltd. boosted its interest in Arvinas by 12.7%. After purchasing an additional 61,087 shares during the most recent quarter, Invesco Ltd. now has 543,797 shares of the company’s stock, valued at a total of $44,668,000. Ally Bridge Group NY LLC increased its ownership percentage in Arvinas by 9.5% during the fourth quarter. After purchasing an additional 20,000 shares during the quarter, Ally Bridge Group NY LLC now has 230,000 shares of the company’s stock, equivalent to $18,892,000. Ensign Peak Advisors Inc. increased its holdings in Arvinas by 194.5% during the fourth quarter of the fiscal year. After purchasing an additional 53,952 shares, Ensign Peak Advisors, Inc. now has a total of 81,692, currently valued at $6,710,000.
Last but not least, Nordea Investment Management AB made a new investment of about 245,000 dollars in Arvinas during the first quarter. At the moment, hedge funds and other types of institutional investors hold a total of 84.52% of the stock. Arvinas, Inc. is a biopharmaceutical firm currently in the clinical stages of its development and is primarily concerned with the discovery, creation, and marketing of treatments that break down disease-causing proteins. ARV-471 is a PROTAC protein degrader that targets the estrogen receptor protein. It is intended to treat patients with metastatic ER-positive or HER2-negative breast cancer. Bavdegalutamide is a PROTAC protein degrader that targets the androgen receptor (AR) protein in phase I clinical trials. Finally, ARV-766 is an investigational orallamycin. These three product candidates are the company’s lead product candidates.